Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betul Oran

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
Blood Advances|April 3, 2020
Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entityAnkur Varma, Susan C Abraham, Rohtesh S Mehta, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Transplantation and Cellular Therapy|May 23, 2022
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple MyelomaAimaz Afrough, Leonard C Alsfeld, Denái R Milton, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
Blood Advances|April 3, 2020
Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entityAnkur Varma, Susan C Abraham, Rohtesh S Mehta, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Journal for Immunotherapy of Cancer|February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantationChantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Transplantation and Cellular Therapy|May 23, 2022
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple MyelomaAimaz Afrough, Leonard C Alsfeld, Denái R Milton, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Pageof 15